Patent intelligence · US
US 11406663
Lanthanum carbonate hydroxide, lanthanum oxycarbonate and methods of their manufacture and use
Lanthanum carbonate hydroxide, lanthanum oxycarbonate and methods of their manufacture and use
Patent details — US 11406663
- Jurisdiction
- US
- Status
- granted
- Grant date
- Aug 9, 2022
- Expiration
- Aug 4, 2042
- Applicant
- UNICYCIVE THERAPEUTICS, INC.
- Claims
- 17
- CPC classes
- A61K, A61K33/244, A61K9/0056, A61K9/0095
Quick answer
US 11406663 (Lanthanum carbonate hydroxide, lanthanum oxycarbonate and methods of their manufacture and use) is held by UNICYCIVE THERAPEUTICS, INC.. Status: granted. Granted Aug 9, 2022. Expires Aug 4, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- UNICYCIVE THERAPEUTICS, INC.
- Grant date
- Expiration
- Claims
- 17
- CPC classes
- A61K, A61K33/244, A61K9/0056, A61K9/0095, A61K9/10, A61K9/1623
More from UNICYCIVE THERAPEUTICS, INC.
Related pharmaceutical patents in our USPTO index.
Frequently asked questions
What is US patent 11406663?
US 11406663 (Lanthanum carbonate hydroxide, lanthanum oxycarbonate and methods of their manufacture and use) is held by UNICYCIVE THERAPEUTICS, INC.. Status: granted. Granted Aug 9, 2022. Expires Aug 4, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11406663?
UNICYCIVE THERAPEUTICS, INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 4 pharmaceutical patents for this assignee.
When does US 11406663 expire?
Our index shows an expiration date of Aug 4, 2042 (16 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.